Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: The SoliRam observational study.

Mohamed Hassanein,Rachid Malek,Inass Shaltout,Rakesh Kumar Sahay,Mehmet Akif Buyukbese,Khier Djaballah,Valerie Pilorget,Mathieu Coudert,Saud Al Sifri

Diabetes & metabolic syndrome（2023）

引用 1|浏览13

暂无评分

摘要

iGlarLixi is an effective and well-tolerated therapy for people with T2D, including those who intend to fast during Ramadan, and is associated with a low risk of hypoglycemia; benefits were observed both during and after Ramadan.

查看译文

关键词

Fasting,Hypoglycemia,Ramadan,Type 2 diabetes,iGlarLixi

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要